|
Median age, years (range)
|
72.0 (59–78)
|
76.0 (66–86)
|
69.0 (63–76)
|
64.5 (50–77)
|
67.5 (52–83)
|
65.0 (49–77)
|
74.5 (53–76)
|
71.0 (49–86)
|
|
Male, n (%)
|
2 (66.7)
|
5 (83.3)
|
7 (77.8)
|
3 (50.0)
|
2 (33.3)
|
4 (57.1)
|
4 (66.7)
|
27 (62.8)
|
|
ECOG PS, n (%)
|
|
0
|
0
|
2 (33.3)
|
5 (55.6)
|
4 (66.7%)
|
3 (50.0)
|
4 (57.1)
|
0
|
18 (41.9)
|
|
1
|
2 (66.7)
|
2 (33.3)
|
4 (44.4)
|
1 (16.7)
|
2 (33.3)
|
2 (28.6)
|
5 (83.3)
|
18 (41.9)
|
|
2
|
1 (33.3)
|
2 (33.3)
|
0
|
1 (16.7)
|
1 (16.7)
|
1 (14.3)
|
1 (16.7)
|
7 (16.3)
|
|
Median disease duration, months (range)
|
5.0 (4.1–6.7)
|
25.8 (8.6–174.4)
|
45.9 (2.3–410.2)
|
37.4 (8.5–341.8)
|
27.4 (5.1–132.2)
|
36.9 (10.0–182.9)
|
99.2 (13.7–196.9)
|
36.9 (2.3–410.2)
|
|
Current malignancy type, n (%)
|
|
AML
|
0
|
3 (50.0)
|
0
|
0
|
3 (50.0)
|
0
|
1 (16.7)
|
7 (16.3)
|
|
JAK2 mutationb, n/N (%)
|
–
|
1/3 (33.3)
|
–
|
–
|
2/3 (66.7)
|
–
|
1/1 (100)
|
4/7 (57.1)
|
|
Myelofibrosis
|
3 (100.0)
|
3 (50.0)
|
9 (100.0)
|
6 (100.0)
|
3 (50.0)
|
7 (100.0)
|
5 (83.3)
|
36 (83.7)
|
|
JAK2 mutationb, n/N (%)
|
2/3 (66.7)
|
2/3 (66.7)
|
8/9 (88.9)
|
5/6 (83.3)
|
3/3 (100)
|
5/7 (71.4)
|
4/5 (80.0)
|
29/36 (80.6)
|
|
Median prior systemic therapies, n (range)
|
1.0 (0–4)
|
3.0 (2–4)
|
1.0 (0–4)
|
2.0 (1–4)
|
2.0 (1–4)
|
2.0 (0–4)
|
3.0 (1–4)
|
3.0 (0–4)
|
|
Median time since last cancer treatment, months (range)
|
2.4 (1.5–3.2)
|
1.2 (0.1–6.3)
|
2.0 (0.5–39.6)
|
8.0 (0.5–37.1)
|
1.5 (0.5–2.4)
|
2.8 (0.7–27.1)
|
6.3 (0.6–21.7)
|
2.2 (0.1–39.6)
|
